Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 6/20 | 0.44 |
| ▸ | PPARG | P37231 | 5/20 | 0.44 |
| ▸ | PPARA | Q07869 | 5/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | CSNK1D | P48730 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9326414 | 0.88 | KDM4E (0.65) | KDM4EKMT2ACA2PPARAGAA | |
| SCHEMBL7340444 | 0.85 | HDAC6 (0.51) | KMT2APPARDMAOBPOLBHSD17B10 | |
| SCHEMBL4695528 | 0.83 | KDM4E (0.51) | KDM4EKMT2ACA2GAAMEN1 | |
| SCHEMBL31716343 | 0.81 | LDHA (0.56) | KDM4EKMT2AGAAMEN1ALDH1A1 | |
| SCHEMBL73741 | 0.81 | RAB9A (0.62) | KDM4EKMT2AGAAALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL3592885 | 0.80 | RAB9A (0.60) | KDM4EKMT2AGAAALDH1A1HSD17B10 | |
| SCHEMBL12596891 | 0.79 | KDM4E (0.79) | KDM4EKMT2AGAAMEN1ALDH1A1 | |
| SCHEMBL8038269 | 0.78 | KDM4E (0.57) | KDM4EGAAMAOBSMN1; SMN2LMNA | |
| SCHEMBL6982961 | 0.78 | KMT2A (0.49) | KDM4EKMT2ACA2GAAMEN1 | |
| SCHEMBL9305118 | 0.77 | RAB9A (0.65) | KDM4EKMT2AGAAMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2081937-B1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| EP-2081937-B1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071581-B2 | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2010-05-13 | — | — | US | disclosed |
| CN-101558070-A | Triazolopyridazine protein kinase modulators | SGX PHARMACEUTICALS INC (US) | 2009-10-14 | — | — | CN | disclosed |
| EP-2081937-A2 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-07-29 | — | — | EP | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051805-A2 | TRIAZOLO-PYRIDAZINE PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CELLTECH R & D LIMITED (GB) | 2003-09-11 | — | — | US | disclosed |
| EP-1311502-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | Celltech R&D Limited (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016353-A1 | BICYCLIC HETEROAROMATIC DERIVATIVES FOR THE TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CELLTECH R & D LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
| US-5288749-A | Treating central nervous system or cardiovascular disorders | ABBOTT LABORATORIES (US) | 1994-02-22 | — | — | US | disclosed |
| WO-1993012754-A2 | TERTIARY AND SECONDARY AMINES AS ALPHA-2 ANTAGONISTS AND SEROTONIN UPTAKE INHIBITORS | ABBOTT LABORATORIES (US) | 1993-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171413-A1 | Bicyclic heteroaromatic derivatives for the treatment of immune and inflammatory disorders | CCR1, CCR3, CCRL2 | KDM4E 3336/4885KMT2A 2399/4885CA2 2349/4885 |
| US-20100120739-A1 | TRIAZOLOPYRIDAZINE PROTEIN KINASE MODULATORS | MAP4K5, MAPKAPK5, MAP4K2 | KDM4E 3016/4885KMT2A 2534/4885CA2 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.